

# In the News

## Global Legal Chronicle: Akeso Biopharma's US\$333 Million Hong Kong IPO

April 28, 2020



### RELATED PROFESSIONALS

#### Ke Geng

Beijing

D: +86-10-6563-4261

#### Ke Zhu

Hong Kong

D: +852-3512-2333

#### Yiming Liu

Shanghai

D: +86-21-2307-7077

#### Qianyu Hu

Hong Kong

D: +852-3512-2361

#### Grace Xu

Hong Kong

D: +852-3512-4057

#### Yiyi Wang

Shanghai

D: +86-21-2307-7065

#### Henry Wong

Hong Kong

D: +852-3512-4032

#### Sydney Ryan

San Francisco

D: +1-415-984-8908

#### Edward Poon

Hong Kong

D: +852-3512-2350

O'Melveny advised Akeso Biopharma (Akeso) in its IPO and listing on the Hong Kong Stock Exchange, this article reported. The IPO offering size is HK\$2.58 billion (US\$330 million), making it 2020's largest Hong Kong IPO to date, *Global Legal Chronicle* reported. Akeso is a leading Chinese clinical-state biotech company specializing in oncology and immunology.

The O'Melveny team that advised Akeso included partners Ke Geng and Ke Zhu, counsel Yiming Liu and Qianyu Hu, and associates Grace Xu, Yiyi Wang, Henry Wong, Sydney Ryan, and Edward Poon, and trainee solicitors Hilda Leung and Dave Chan.

Read the full article [here](#).

### RELATED PRACTICES

[Capital Markets](#)